Measurement of Quality of Life in Primary Sjögren’s Syndrome

  • Simon J. Bowman
  • Wan-Fai Ng


Primary Sjögren’s syndrome (PSS) is an immune-mediated rheumatic disease in which inflammation of secretory (exocrine) glands leads to dry eyes and dry mouth [1]. Dryness of other surfaces such as the skin, vagina, airways, and gastrointestinal tract also occurs. The secretory glands are infiltrated by collections (focal aggregations) of lymphocytes. In the salivary glands, these focal lymphocyte aggregations are typically clustered around the salivary ducts. Patients typically also complain of reduced well-being, fatigue, and arthralgia. Approximately three-quarters of patients have autoantibodies in their blood – anti-Ro and/or anti-La antibodies – and a majority also have elevated total immunoglobulin levels (hypergammaglobulinaemia).


HRQoL Measure Oral Health Impact Profile Ocular Surface Disease Index Physical Composite Score Mental Composite Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Acknowledgements and Conflicts of Interest

WFN has received salary support from the Arthritis Research Campaign and grant support from the Medical Research Council, Arthritis Research Campaign, British Sjögren’s Syndrome Association and the JGW Patterson Foundation. The UK Primary Sjögren’s Syndrome Registry is funded by the Medical Research Council. SJB has consulted for Roche, Genentech, UCB, Glaxo-Smith-Kline and Astra-Zeneca and has received grant support from the Arthritis Research Campaign, University Hospital Birmingham Charities and the British Sjögren’s Syndrome Association.


  1. 1.
    Jonsson R, Bowman SJ, Gordon TP. Sjögren’s Syndrome. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions, Chapter 78. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1681–705.Google Scholar
  2. 2.
    Carr AJ, Thompson PW, Kirwan JR. Quality of life measures. Br J Rheumatol. 1996;35:275–81.PubMedCrossRefGoogle Scholar
  3. 3.
    WHOQOL Group. Development of the WHOQOL: rationale and current status. Int J Ment Health. 1994;23:24–56.Google Scholar
  4. 4.
    WHOQOL Group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol Med. 1998;28:551–8.CrossRefGoogle Scholar
  5. 5.
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Centre; 1993.Google Scholar
  6. 6.
    Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren’s syndrome: a community based study of prevalence and impact. Br J Rheumatol. 1998;37:1069–76.PubMedCrossRefGoogle Scholar
  7. 7.
    Strömbeck B, Ekdahl C, Manthorpe R, et al. Health-related quality of life in primary Sjogren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol. 2000;29:20–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Tensing EK, Solovieva SA, Tervahartiala T, et al. Fatigue and health profile in sicca syndrome of Sjogren’s and non-Sjogren’s syndrome origin. Clin Exp Rheumatol. 2001;19:313–6.PubMedGoogle Scholar
  9. 9.
    Rostron J, Rogers S, Longman L, et al. Health-related quality of life in patients with primary Sjogren’s syndrome and xerostomia: a comparative study. Gerodontology. 2002;19:53–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Bowman SJ, Booth DA, Platts RG, UK Sjögren’s Interest Group. Measurement of fatigue and discomfort in primary Sjogren’s syndrome using a new questionnaire tool. Rheumatology (Oxford). 2004;43:758–64.CrossRefGoogle Scholar
  11. 11.
    Belenguer R, Ramos-Casals M, Brito-Zerón P, et al. Influence of clinical and immunological parameters on the health-related quality of life in patients with primary Sjogren’s syndrome. Clin Exp Rheumatol. 2005;23:351–6.PubMedGoogle Scholar
  12. 12.
    Champey J, Corruble E, Gottenberg JE, et al. Quality of life and psychological status in patients with primary Sjogren’s syndrome and sicca symptoms without autoimmune features. Arthritis Rheum. 2006;55:451–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Stewart CM, Berg KM, Cha S, Reeves WH. Salivary dysfunction and quality of life in Sjogren’s syndrome: a critical oral-systemic connection. J Am Dent Assoc. 2008;139:291–9.PubMedGoogle Scholar
  14. 14.
    López-Jornet P, Camacho-Alonso F. Quality of life in patients with Sjogren’s syndrome and sicca complex. J Oral Rehabil. 2008;35:875–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford). 2009;48:1077–82.CrossRefGoogle Scholar
  16. 16.
    Segal B, Bowman SJ, Fox PC, et al. Primary Sjogren’s syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009;27:7–46.Google Scholar
  17. 17.
    Baturone R, Soto M, Marquez M, et al. Health-related quality of life in patients with primary Sjogren’s syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol. 2009;2:1–4.Google Scholar
  18. 18.
    Sutcliffe N, Stoll T, Pyke S, Isenberg D. Functional disability and end-organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren’s syndrome (SS), and primary SS. J Rheumatol. 1998;25:63–8.PubMedGoogle Scholar
  19. 19.
    Group EuroQoL. EuroQoL – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRefGoogle Scholar
  20. 20.
    Rajagopalan K, Abetz L, Mertzanis P, et al. Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye. Value Health. 2005;8:168–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Seror R, Ravaud P, Bowman S, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren’s syndrome. Ann Rheum Dis. 2009;69:1103–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Ng WF, Griffiths B, Griffiths ID, Bowman SJ. United Kingdom primary Sjogren’s syndrome registry (UKPSSR). London: Medical Research Council; 2008.Google Scholar
  23. 23.
    Hunt SM, McEwan J. The development of a subjective health indicator. Sociol Health Illn. 1980;2:231–46.PubMedCrossRefGoogle Scholar
  24. 24.
    Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65:1304–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Valtysdottir ST, Gudbjornsson B, Lindqvist U, et al. Anxiety and depression in patients with primary Sjogren’s syndrome. J Rheumatol. 2000;27:165–9.PubMedGoogle Scholar
  26. 26.
    Bowman SJ. Patient-reported outcomes including fatigue in primary Sjogren’s syndrome. Rheum Dis Clin North Am. 2008;34:949–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Bowman SJ, Booth DA, Platts RG, et al. Validation of the sicca symptoms inventory for clinical studies of Sjogren’s syndrome. J Rheumatol. 2003;30:1259–66.PubMedGoogle Scholar
  28. 28.
    Slade GD, Spencer AJ. Development and evaluation of the Oral Health Impact Profile. Community Dent Health. 1994;11:3–11.PubMedGoogle Scholar
  29. 29.
    Allen PF, McMillan AS, Walshaw D, Locker D. A comparison of the validity of generic and disease-specific measures in the assessment of oral health-related quality of life. Community Dent Oral Epidemiol. 1999;27:344–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Allen PF, McMillan AS, Locker D. An assessment of sensitivity to change of the Oral Health Impact Profile in a clinical trial. Community Dent Oral Epidemiol. 2001;29:175–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Lopez-Jornet P, Camacho-Alonso F. Quality of life in patients with Sjogren’s syndrome and sicca complex. J Oral Rehabil. 2008;35:875–81.PubMedCrossRefGoogle Scholar
  32. 32.
    McMillan AS, Leung KC, Leung WK, et al. Impact of Sjogren’s syndrome on oral health-related quality of life in southern Chinese. J Oral Rehabil. 2004;31:653–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Larsson P, List T, Lundström I, et al. Reliability and validity of a Swedish version of the Oral Health Impact Profile (OHIP-S). Acta Odontol Scand. 2004;62:147–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Barcelos F, Patto JV, Parente M, et al. Applicability of sialometry and other instruments to evaluate xerostomia and xerophthalmia in a Sjogren’s syndrome outpatient clinic. Acta Reumatol Port. 2009;34:212–8.PubMedGoogle Scholar
  35. 35.
    McGrath C, Bedi R, Bowling A. Evaluation of OHQoL-UK(c): a measure of oral health related quality of life. J Dent Res. 1999;78:1051.Google Scholar
  36. 36.
    Locker D, Matear D, Stephens M, et al. Comparison of the GOHAI and OHIP-14 as measures of the oral health-related quality of life of the elderly. Community Dent Oral Epidemiol. 2001;29:373–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol. 2001;37:84–93.PubMedCrossRefGoogle Scholar
  38. 38.
    Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21.PubMedGoogle Scholar
  39. 39.
    Vitale S, Goodman LA, Reed GF, Smith JA. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjogren’s syndrome-related dry eye. Health Qual Life Outcomes. 2004;2:44.PubMedCrossRefGoogle Scholar
  40. 40.
    Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). Arch Ophthalmol. 1998;116:1496–504.PubMedGoogle Scholar
  41. 41.
    d’Elia HF, Bjurman C, Rehnberg E, et al. Interleukin 6 and its soluble receptor in a central role at the neuroendocrine interface in Sjogren’s syndrome: an exploratory interventional study. Ann Rheum Dis. 2009;68:285–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Hartkamp A, Geenen R, Bijl M, et al. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren’s syndrome. Ann Rheum Dis. 2004;63:1335–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Segal B, Thomas W, Rogers T, et al. Prevalence, severity and predictors of fatigue in subjects with primary Sjogren’s syndrome. Arthritis Rheum. 2008;59:1780–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Bowman SJ, Sutcliffe N, Isenberg DA, et al. Sjogren’s systemic clinical activity index (SCAI): a systemic disease activity measure for use in clinical trials in primary Sjogren’s syndrome. Rheumatology (Oxford). 2007;46:1845–51.CrossRefGoogle Scholar
  45. 45.
    Barry RJ, Sutcliffe N, Isenberg DA, et al. The Sjogren’s Syndrome Damage Index: a damage index for use in clinical trials and observational studies in primary Sjogren’s syndrome. Rheumatology (Oxford). 2008;47:1193–8.CrossRefGoogle Scholar
  46. 46.
    Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomised studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107:631–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren’s syndrome. Arch Intern Med. 1999;159:174–81.PubMedCrossRefGoogle Scholar
  48. 48.
    Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52:360–4.PubMedCrossRefGoogle Scholar
  49. 49.
    Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren’s syndrome. Results of the randomised, controlled trial of Remicade in primary Sjogren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740–50.PubMedCrossRefGoogle Scholar
  51. 51.
    Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren’s syndrome with rituximab: extended follow-up, safety and efficacy of treatment. Ann Rheum Dis. 2009;68:284–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjogren’s syndrome after two infusions of rituximab (anti CD20). Arthritis Rheum. 2007;57:310–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren’s syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Hartkamp A, Geenen R, Godaert GL, et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren’s syndrome: a randomised controlled trial. Ann Rheum Dis. 2008;67:91–7.PubMedCrossRefGoogle Scholar
  55. 55.
    van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjogren’s syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66:1026–32.PubMedCrossRefGoogle Scholar
  56. 56.
    Strombeck BE, Theander E, Jacobsson LT. Effects of exercise on aerobic capacity and fatigue in women with primary Sjogren’s syndrome. Rheumatology (Oxford). 2007;46:868–71.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Simon J. Bowman
    • 1
  • Wan-Fai Ng
    • 2
  1. 1.Rheumatology DepartmentUniversity Hospital Birmingham (Selly Oak)BirminghamUK
  2. 2.Musculoskeletal Research Group, Institute of Cellular MedicineNewcastle UniversityNewcastle Upon TyneUK

Personalised recommendations